Related Experiment Videos
Postmenopausal osteoporosis: cause, prevention and treatment
Clinics in Obstetrics and Gynaecology
|April 1, 1977
Summary
Low-dose estrogen may prevent postmenopausal osteoporosis, reducing fractures and mortality. Further research is needed to determine the minimal effective prophylactic dose to avoid side effects.
Area of Science:
- Endocrinology
- Gerontology
- Bone Metabolism
Background:
- Postmenopausal osteoporosis is a significant health concern, leading to fractures and increased mortality.
- Current treatments with full-dose estrogen are effective but may be considered late-stage interventions.
Purpose of the Study:
- To explore the potential of low-dose estrogen for preventing postmenopausal bone loss.
- To identify a prophylactic dose of estrogen that prevents bone loss without causing endometrial hyperplasia.
Main Methods:
- Review of existing studies on estrogen dosage for osteoporosis prevention.
- Analysis of data from trials using mestranol (20 mcg) and conjugated estrogens (0.625 mg).
Main Results:
- Smaller doses of estrogen (mestranol 20 mcg, conjugated estrogens 0.625 mg) show promise in preventing bone loss at menopause.
- The minimal effective prophylactic dose has not yet been established.
Conclusions:
- Low-dose prophylactic estrogen therapy holds potential for preventing postmenopausal osteoporosis.
- This approach could significantly reduce the incidence of vertebral, wrist, and hip fractures and associated mortality.